GOG 172:IV PACLITAXEL & CISPLATIN VS IV PACLITAXEL IN EPITHELIAL OVAR

最佳的III期卵巢癌或原发性腹膜癌的标准治疗是静脉注射顺铂和紫杉醇的化疗。本研究的目的是确定在静脉化疗的基础上加用腹腔化疗与目前标准的静脉化疗相比的有效性。由于卵巢癌在腹膜腔内扩散，向腹膜腔内注入化疗药物可能会导致更大剂量的药物进入肿瘤细胞。这项研究将评估标准静脉注射顺铂和紫杉醇与静脉注射紫杉醇和腹腔注射顺铂和紫杉醇时患者的反应和存活/无病间隔。这项研究还将评估治疗对患者生活质量的影响。

The standard treatment for optimally debulked Stage III ovarian or primary peritoneal carcinoma is chemotherapy with intravenous Cisplatin and Paclitaxel. The purpose of this study is to determine the effectiveness of administration of chemotherapy into the abdominal cavity in addition to intravenous chemotherapy compared to the current standard intravenous chemotherapy. Because ovarian cancer spreads in the abdominal cavity, giving chemotherapy by infusion into the abdominal cavity may result in a greater dose of the drugs reaching tumor cells. This study will evaluate the patient's response, and survival/disease free interval when treated with standard intravenous Cisplatin and Paclitaxel compared to intravenous Paclitaxel and intraperitoneal Cisplatin and Paclitaxel. The study will also evaluate the impact of treatment on the patient's quality of life.